AbbVie Inc. , a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
$256.46
▼ -$3.75 (-1.44%)Today
Open
$257.96
High
$258.91
Low
$255.61
Volume
4.7M
$190.7552-Week Range$267.47
Current: $256.46 · Near 52W High
MARKET CAP
$453.2B
P/E (TTM)
72.4x
P/B RATIO
—
ROE
—
EPS (TTM)▲ 10.2% Rev YoY
$3.54
DIVIDEND YIELD
2.70%
BETA
0.28
Defensive / low-beta
Company Info
Industry
Drug Manufacturers - General
Country
United States
Leadership
DA
Dr. Azita Saleki Ph.D.
Chief Executive Officer
Stock Score
High Quality23/ 100
Val
9
Grw
26
Qly
40
Value 40%·Growth 35%·Quality 25%
Price History
$256.46▲ $46.67 (22.25%)
Overlays
Oscillators
Generating analysis...
01 / Income Statement
Income Statement
Revenue & Margin Trend
| Period | Revenue | OpEx | EBITDA | Net Income | EPS |
|---|---|---|---|---|---|
| 2022 | $58.05B | $21.83B | $24.17B | $11.84B | $6.63 |
| 2023 | $54.32B▼ | $20.37B | $17.17B | $4.86B▼ | $2.72 |
| 2024 | $56.33B▲ | $27.54B | $14.91B | $4.28B▼ | $2.39 |
| 2025 | $61.16B▲ | $22.86B | $17.63B | $4.23B▼ | $2.36 |
02 / Balance Sheet
Balance Sheet
Cash & Equivalents
$5.23B
Total Debt
$67.50B
Assets Distribution
Current Assets
Non-Current Assets
Liabilities & Equity
Current Liabilities
Non-Current Liabilities
Equity
03 / Cash Flow
Cash Flow
Positive free cash flow of $17.8B — 94% of operating cash flow.
Operating CF
$19B
Free Cash Flow
$17.8B
Investing CF
-$6.6B
Financing CF
-$12.7B
Cash Flow Mix
Operating Cash$19B
Investing Cash-$6.6B
Financing Cash-$12.7B
Net Change-$337M
FCF Generation
The company converts 94% of operating cash flow into free cash flow, providing ample flexibility for capital allocation.
CapEx Burden
Capital expenditures consume $6.6B of operating cash. Monitor for maintenance vs. growth CapEx split.
Is the cash flow sustainable?
Positive Free Cash Flow
The company has flexibility for dividends, buybacks, debt reduction, or reinvestment in growth opportunities.
04 / Financial Ratios
Financial Ratios
Profitability
Gross Margin
70.2%
Gross Profit / Revenue
Operating Margin
32.8%
Op. Income / Revenue
Net Margin
6.9%
Net Income / Revenue
ROIC
6.6%
Return on Invested Capital
Liquidity & Leverage
Current Ratio
0.67x
Current Assets / Current Liab.
Cash Ratio
0.12x
Cash / Current Liab.
Debt-to-Equity
N/A
Total Debt / Equity
Asset Turnover
0.46
Revenue / Total Assets
Returns
ROE
N/A
Return on Equity
ROA
10.5%
Return on Assets
EPS (TTM)
$3.54
Earnings Per Share
06 / Historical Trends
Historical Trends
Revenue
+1.8% CAGRNet Income
-29.1% CAGREPS
-29.1% CAGR05 / Dividends
Dividends & Yield
Dividend Yield
2.70%
Annual
Annual Dividend
$6.92
Per Share
Payout Ratio
195.6%
Div / EPS
Est. Div Growth
+4.1%
Approx. YoY
Dividend Safety Assessment
The payout ratio of 196% is elevated and may be at risk if earnings decline.
Recent Dividend Payments
| Date | Amount |
|---|---|
| 2026-07-15 | $1.73 |
| 2026-04-15 | $1.73 |
| 2026-01-16 | $1.73 |
| 2025-10-15 | $1.64 |
| 2025-07-15 | $1.64 |
| 2025-04-15 | $1.64 |
| 2025-01-15 | $1.64 |
| 2024-10-15 | $1.55 |
| 2024-07-15 | $1.55 |
| 2024-04-12 | $1.55 |
Institutional Ownership
Moderate Institutional Support
Top 3 institutional holders control 19.7% of shares, providing a stable foundation of institutional capital.
Retail Influence
Lower institutional concentration means retail sentiment and broader market trends may drive price action more noticeably.
Top Institutional Holders
Blackrock Inc.8.46%
149.49M shares
Vanguard Capital Management LLC6.53%
115.4M shares
State Street Corporation4.67%
82.6M shares
Vanguard Portfolio Management LLC2.74%
48.48M shares
JPMORGAN CHASE & CO2.71%
47.86M shares
Top ETFs Holding
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.17%
56.09M shares
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.59%
45.78M shares
iShares Trust-iShares Core S&P 500 ETF1.38%
24.3M shares
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.29%
22.85M shares
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.21%
21.41M shares
07 / Market Events
Market Events
Upcoming Earnings
OCT
29THU
DateOct 29, 2026
DayThursday
Revenue Est.$17.3B
EPS Est.$3.84
08 / Market Intelligence
Market Intelligence
Analyst Consensus
Consensus (31 Ratings)
Buy
Strong Buy
8
Buy
17
Hold
5
Sell
0
Strong Sell
1
Recent Insider Trades
DONOGHOE NICHOLAS
Officer
Sale
32,710 shs
DONOGHOE NICHOLAS
Officer
Sale
32,710 shs
FREYMAN THOMAS C
Director
Sale
1,118 shs
FALK THOMAS J
Director
Sale
1,118 shs
Price Targets
Upside to Mean+7.8%
$200$277$328
Low
$200.00
Mean
$276.59
Median
$280.00
High
$328.00
Earnings History
Beat Rate
3/4
Avg Surprise
+1.7%
| Period | Est. EPS | Act. EPS | Surprise |
|---|---|---|---|
| 2025-09 | $1.78 | $1.86 | +4.2% |
| 2025-12 | $2.65 | $2.71 | +2.2% |
| 2026-03 | $2.67 | $2.65 | -0.8% |
| 2026-06 | $3.61 | $3.65 | +1.1% |